Matches in SemOpenAlex for { <https://semopenalex.org/work/W2737664341> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2737664341 endingPage "e14030" @default.
- W2737664341 startingPage "e14030" @default.
- W2737664341 abstract "e14030 Background: In Phase I oncology trials the primary goal is to assess dose limiting toxicities (DLT) and estimate the maximum tolerated dose (MTD). The classical 3+3 design is still used in greater than 90% of studies. We review the classical 3+3 design and two new model-based designs: Bayesian Optimal Interval (BOIN) design and the recently updated modified toxicity probability interval (mTPI-2) design. These designs are easy to implement like the 3+3 using a simple table to guide dose escalation/de-escalation. As opposed to the 3+3 design, these designs can target a DLT rate well above or below the standard 33% target. In general, an expansion cohort is added to 3+3 designs to verify safety and get an early efficacy signal. In the 3+3 expansion cohort it is unclear how to proceed if excessive toxicity is observed; whereas, with BOIN and mTPI-2, expansion can be built in with toxicity monitoring and MTD updating. Methods: We carefully explain how computer simulations can be used to evaluate phase I designs and present results from simulations comparing the designs under several true dose toxicity curves. Results: We show that BOIN and mTPI-2 have better performance than the 3+3. These new designs select the true MTD at a much higher rate and treat a higher percentage of patients at the MTD. The new designs generally tend to allocate fewer patients to high toxicity doses and fewer patients to low toxicity doses, thus ensuring high ethical standards. Unlike older Bayesian designs (e.g., modified continual reassessment method), the newer designs do not require a statistician to update the model during the course of the trial. Readily available, free software make these designs simple to implement. Conclusions: We recommend the use of the new model-based designs over the classical 3+3 design." @default.
- W2737664341 created "2017-07-31" @default.
- W2737664341 creator A5005194857 @default.
- W2737664341 creator A5080656521 @default.
- W2737664341 date "2017-05-20" @default.
- W2737664341 modified "2023-09-25" @default.
- W2737664341 title "Phase I clinical trials in oncology: A review of the old and a look at the new." @default.
- W2737664341 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14030" @default.
- W2737664341 hasPublicationYear "2017" @default.
- W2737664341 type Work @default.
- W2737664341 sameAs 2737664341 @default.
- W2737664341 citedByCount "1" @default.
- W2737664341 countsByYear W27376643412021 @default.
- W2737664341 crossrefType "journal-article" @default.
- W2737664341 hasAuthorship W2737664341A5005194857 @default.
- W2737664341 hasAuthorship W2737664341A5080656521 @default.
- W2737664341 hasConcept C126322002 @default.
- W2737664341 hasConcept C127413603 @default.
- W2737664341 hasConcept C143998085 @default.
- W2737664341 hasConcept C148482608 @default.
- W2737664341 hasConcept C188198153 @default.
- W2737664341 hasConcept C2777334693 @default.
- W2737664341 hasConcept C29730261 @default.
- W2737664341 hasConcept C44249647 @default.
- W2737664341 hasConcept C535046627 @default.
- W2737664341 hasConcept C71924100 @default.
- W2737664341 hasConcept C72563966 @default.
- W2737664341 hasConcept C78519656 @default.
- W2737664341 hasConceptScore W2737664341C126322002 @default.
- W2737664341 hasConceptScore W2737664341C127413603 @default.
- W2737664341 hasConceptScore W2737664341C143998085 @default.
- W2737664341 hasConceptScore W2737664341C148482608 @default.
- W2737664341 hasConceptScore W2737664341C188198153 @default.
- W2737664341 hasConceptScore W2737664341C2777334693 @default.
- W2737664341 hasConceptScore W2737664341C29730261 @default.
- W2737664341 hasConceptScore W2737664341C44249647 @default.
- W2737664341 hasConceptScore W2737664341C535046627 @default.
- W2737664341 hasConceptScore W2737664341C71924100 @default.
- W2737664341 hasConceptScore W2737664341C72563966 @default.
- W2737664341 hasConceptScore W2737664341C78519656 @default.
- W2737664341 hasIssue "15_suppl" @default.
- W2737664341 hasLocation W27376643411 @default.
- W2737664341 hasOpenAccess W2737664341 @default.
- W2737664341 hasPrimaryLocation W27376643411 @default.
- W2737664341 hasRelatedWork W1971341357 @default.
- W2737664341 hasRelatedWork W2114520074 @default.
- W2737664341 hasRelatedWork W2150700051 @default.
- W2737664341 hasRelatedWork W2163989736 @default.
- W2737664341 hasRelatedWork W2252231371 @default.
- W2737664341 hasRelatedWork W2603773853 @default.
- W2737664341 hasRelatedWork W2737417319 @default.
- W2737664341 hasRelatedWork W2946639201 @default.
- W2737664341 hasRelatedWork W3168107787 @default.
- W2737664341 hasRelatedWork W4361015616 @default.
- W2737664341 hasVolume "35" @default.
- W2737664341 isParatext "false" @default.
- W2737664341 isRetracted "false" @default.
- W2737664341 magId "2737664341" @default.
- W2737664341 workType "article" @default.